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Background: In acute liver failure (ALF) therapeutic plasma exchange (TPE) improves laboratory measures of liver
function. In patients with ALF requiring minimal vasoactive support TPE has also been shown to provide
haemodynamic benefits including an increase in systemic blood pressure. However the haemodynamic effects of
TPE in patients with severe ALF requiring moderate or high dose vasopressor therapy has not been reported. We
retrospectively examined the haemodynamic effects of TPE in a cohort of patients with severe ALF requiring
vasopressor therapy.
Methods: Physiological, laboratory and treatment data were collected on all patients with ALF who received TPE
between January 2000 and December 2012. All patients were managed in the intensive care unit of a tertiary
referral centre for ALF and liver transplantation.
The primary outcome measures were changes in mean arterial pressure (MAP), vasopressor score and the ratio of
vasopressor score to MAP (vasopressor dependency index (VDI)) from baseline prior to TPE through to 12 hours
after completion of TPE. Secondary outcome measures were changes in other routinely collected physiological
variables and laboratory results. Results are presented as median (interquartile range (IQR)). Outcome measures
were evaluated using a mixed effect model.
Results: Thirty nine TPE were performed in 17 patients with ALF (13 paracetamol poisoning). All TPE were
performed with a centrifugal apheresis system (duration 130 minutes (IQR 115 – 147.5), plasma volume removed
5.1% body weight (IQR 4.6 – 5.5). Baseline values for primary outcome measures were: MAP 82 mmHg (IQR 72 – 92.5),
vasopressor score 8.35 (IQR 3.62 – 24.6) and VDI 0.10 (IQR 0.05 – 0.31).
MAP was significantly higher immediately after TPE compared to baseline (p = 0.039), however when corrected for
change in vasopressor requirement there was no significant change in VDI with TPE (p = 0.953). Twelve hours after TPE
the MAP, vasopressor score and VDI were not significantly different from baseline (p = 0.563, p = 0.317 and p = 0.214
respectively).
Conclusion: In this cohort of patients with severe ALF centrifugal TPE did not significantly affect vasopressor
requirements.
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Acute liver failure (ALF) is defined as the rapid onset of
encephalopathy and coagulopathy after the onset of
jaundice in patients with no known previous liver dis-
ease [1]. In severe cases multiple organ systems are af-
fected, but with no known curative therapy, treatment is
aimed at providing physiological support and preventing
irreversible intracranial hypertension until, either a suit-
able cadaveric liver becomes available for transplant-
ation, or spontaneous recovery of liver function occurs
[2,3]. Prolonged supportive therapy may be necessary in
regions with a small potential donor pool, or where
transplantation is contraindicated. A central component
of supportive care is vasopressor therapy for distributive
shock.
In the setting of ALF therapeutic plasma exchange
(TPE) with fresh frozen plasma as the replacement fluid
improves laboratory measures of coagulation [4-7],
facilitating invasive procedures, without the risk of
excessive fluid loading. Furthermore liver enzyme and
ammonia levels are reduced [5-8], but whether there is
an improvement in outcome (transplant free survival)
remains uncertain [3,9]. Larsen and colleagues demon-
strated potentially beneficial haemodynamic effects of
TPE in ALF, with an increase in blood pressure and re-
duction in cardiac output without a change in oxygen
consumption [10,11]. However, these results were ob-
tained in a small series of patients requiring little or no
vasoactive therapy (dopamine or dobutamine only).
At our institution TPE is used in selected patients with
severe ALF most of whom require moderate or high
dose vasopressor therapy to maintain a clinically accept-
able blood pressure. The primary aim of this study was
to retrospectively examine our experience of the haemo-
dynamic effects of TPE in ALF, particularly the temporal
effect on vasopressor requirements. Secondarily, we ana-
lysed the effect of TPE on respiratory, coagulation and
biochemical variables.
Methods
This retrospective study was conducted in the intensive
care unit (ICU) of a university teaching hospital and
referral centre for acute liver failure and liver trans-
plantation. Approval for the study was obtained from
the Southern Adelaide Clinical Human Research Ethics
Committee. Informed consent was waived as data collec-
tion and analyses were anonymised.
Patients and treatment
All patients with a diagnosis of ALF who presented to
the hospital between January 2000 and June 2012, and
who underwent TPE, were identified from a compu-
terised database for TPE held in the hospital transfusion
service. Patient demographic and clinical informationwas obtained from historical case notes. Physiological and
therapeutic data (hourly recordings) were obtained from
historical ICU 24 hour flow charts. Laboratory results
were obtained from the hospital computerised laboratory
results system (Oacis Clinical Care Suite, Dinmar, USA).
TPE data were obtained from the hospital transfusion
service TPE database. Liver transplant listing data was
obtained from the hepatology service liver transplant
database.
All patients underwent TPE with a Spectra Optia aphe-
resis system (Terumo BCT Inc, Lakewood, Colorado,
USA). Citrate based anticoagulation was used with every
TPE. Intravenous calcium therapy was given as required
for hypocalcaemia. All treatments were performed in the
ICU. All patients had invasive arterial and venous blood
pressure monitoring in situ.
For each patient demographic data were collected for
age, weight, cause of acute liver failure, time from ad-
mission to ICU until first TPE treatment, liver transplant
listing, liver transplantation, severity of illness (APACHE
III and SAPS II), treatment with N-acetylcysteine, renal
replacement therapy, use of intracranial pressure moni-
toring and mortality.
Measurements
For each TPE the following treatment variables were col-
lected: start time, finish time, volume processed, volume
removed (effective dose of TPE), volume replaced, type
of replacement fluid, total acid-citrate-dextrose volume
used and acid-citrate-dextrose volume received by pa-
tient. Patient physiological and laboratory values were
collected at the following time points relative to each
TPE: within 1 hour before treatment (pre-treatment),
each hour during treatment, and at 1, 2, 3, 6 and
12 hours after TPE completed. The following physio-
logical and laboratory values were collected at those
time points: heart rate, systolic blood pressure, diastolic
blood pressure, mean arterial pressure (MAP), central
venous pressure, patient temperature, fluid balance (net
input and output from a baseline within 1 hour before
treatment), vasoactive infusion rates, arterial pH, inspired
oxygen concentration (FiO2), partial pressure of carbon
dioxide (PaCO2), partial pressure of oxygen (PaO2) and
Base Excess, whole blood concentrations of haemoglobin,
bicarbonate, sodium, potassium, chloride, glucose, lactate,
fibrinogen and ionized calcium, plasma concentrations of
albumin and bilirubin, and whole blood International nor-
malised ratio (INR) and activated partial thromboplastin
time (APTT).
In view of the use of different vasoactive agents in
different patients and at different times the combined
dose of vasoactive agents, taking into account their
relative potency, is expressed using a vasopressor score.
In this study the vasopressor score was calculated as
Figure 1 Patient outcome according to liver transplant status.
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100 μg/kg/min) + (vasopressin dose × 10000 units/kg/min),
which is a modification of the vasoactive-inotropic score
described by Gaies et al. to exclude milrinone [12]. No pa-
tients received dopamine or dobutamine. In clinical prac-
tice the vasopressor dose is periodically titrated according
to blood pressure. Therefore the degree of vasopressor
support was also expressed as the vasopressor dependency
index (VDI), calculated as the ratio of vasopressor score
to MAP [13]; thus the greater the amount of vasopressor
therapy the higher the VDI.
Statistical analysis
Descriptive data are expressed as median with interquar-
tile range (IQR). Statistical analysis was conducted using
Stata 13 (StataCorp, Texas, USA) with data expressed as
mean ± standard error (SE). Linear mixed effects models
were used to estimate the effect of TPE on MAP, vaso-
pressor score and VDI with time (pre-, 1 hour post-
treatment (P1) and 12 hours post-treatment (P12)) as
fixed effects and each patient and repetition of therapy
(between 1 and 6 treatments per patient) nested within
each patient as random effects. Other variables that may
have affected the response to TPE were included as co-
variates; these were: pH, lactate and presence or absence
of renal replacement therapy just prior to TPE. The final
models only included covariates that had p values of less
than 0.05.
The effect of TPE on heart rate, pulse pressure, central
venous pressure, patient temperature, net fluid balance,
pH, PaO2/FiO2, lactate, bilirubin, INR and APTT was
estimated using a mixed effect model with the same pre-
dictors listed above plus bilirubin. Only variables that
were significant at the 10% level in univariate analysis
were included for examination in the multivariate model.
Therefore the predictors included for each outcome
variable are different. Statistical significance was defined
as p value less than 0.05.
Results
Patients
A total of 39 TPE treatments were performed on 17
patients with ALF during the study period; median 2
(interquartile range (IQR) 1–3) TPE treatments per pa-
tient. All TPE treatments were included for analysis. The
median age was 40 years (IQR 29–45). There were 13 fe-
males (76.5%) and 4 males (23.5%). The median weight
(IQR) was 60 kg (55–64.5). The median severities of
illness (IQR) scores were: APACHE III 107.5 (86–124),
SAPS II 55.0 (43.75-66.25). The causes of ALF were:
paracetamol toxicity 13 patients, alcoholic hepatitis 2
patients, Budd Chiarri syndrome 1 patient and herbal rem-
edy ingestion 1 patient. Five patients had intracranial pres-
sure monitoring during at least one of their treatmentswith TPE. There were insufficient data to determine the
effect of TPE on intracranial pressure. Patient outcome
according to liver transplant status is shown in Figure 1.
Six patients survived and 11 patients died.Therapeutic plasma exchange
The replacement fluid for the first TPE treatment for
every patient was 100% fresh frozen plasma. Additional
TPE treatments were performed with 100% fresh frozen
plasma for 17 treatments in 13 patients, a combination
of fresh frozen plasma and cryoprecipitate for 4 treat-
ments in 4 patients, and a combination of fresh frozen
plasma and 4% albumin for 1 treatment. Other TPE
treatment variables are shown in Table 1.Baseline results
Baseline laboratory results from samples taken before
each TPE are shown in Table 2.
At baseline MAP was significantly higher when the base-
line pH was higher (31.9 ± 10.1 mmHg for every unit
increase in pH (p = 0.002)). Conversely, MAP was inversely
related to baseline lactate (0.86 ± 0.37 mmHg lower
MAP for every mmol/L increase in lactate (p = 0.021)).
Vasopressor score and VDI were significantly higher when
baseline pH was lower (both p < 0.001) and when baseline
lactate was higher (both p < 0.001). For every unit decrease
in pH the vasopressor score was 62.0 ± 14.7 higher and the
VDI was 0.82 ± 0.22 units higher. For every mmol/L in-
crease in lactate the vasopressor score was 2.04 ± 0.55
higher and the VDI was 0.04 ± 0.01 units higher. Patients
receiving renal replacement therapy just prior to TPE had
a higher MAP (p = 0.017) and higher vasopressor score
(p = 0.001) than those not receiving renal replacement
therapy, thus there was no significant difference in VDI
between the two groups.
Table 1 TPE treatment variables
Time from admission to ICU to first TPE
treatment (hours) median (IQR)
16.67 (2.75-34.67)
Blood volume processed (ml) median (IQR) 5012 (4373–6147)
Blood volume processed as % body weight
(ml/kg) median (IQR)
8.4 (7.9-9.5)
Plasma volume removed (ml) median (IQR) 3000 (2689–3390)
Plasma volume removed as % of body
weight (ml/kg) median (IQR)
5.1 (4.6-5.5)
Citrate dose received by patient (mmol)
median (IQR)
27.0 (24.8-31.8)
Net patient fluid balance during TPE (ml)
median (IQR)
267 (−305-433)
Duration of TPE (minutes) median (IQR) 130 (115–148)
Number of TPE treatments with renal
replacement therapy immediately before
and/or after
Before and after TPE 23
Before TPE only 2
After TPE only 9
Neither 5
Ionised Calcium level pre TPE (mmol/L)
median (IQR) (laboratory values only
available for 34 TPE)
1.05 (0.95-1.16)
Lowest ionised Calcium level during TPE
(mmol/L) median (IQR) (laboratory values
only available for 33 TPE)
0.87 (0.71-0.94)
Ionised Calcium level post TPE (mmol/L)
median (IQR) (laboratory values only
available for 15 TPE)
1.11 (0.99-1.25)
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The temporal trends in MAP, vasopressor score and
VDI for every TPE performed are shown in Figure 2.
The temporal trends in VDI for the first TPE treatment
for each patient are shown in Figure 3. The temporal
trends in MAP and vasopressor score for the first TPE
treatment for each patient are shown in Additional files
1 and 2. For 7 TPE treatments in 4 patients the patient
did not require any vasoactive agent at some (1 TPE) or
all time points (6 TPE in 3 patients). The VDI was thusTable 2 Baseline laboratory results prior to TPE
treatments
Laboratory test Pre TPE value median (IQR)
PaO2/FiO2 ratio 248 (166–371)
pH* 7.38 (7.18-7.47)
pH prior to first TPE for each patient* 7.23 (7.07-7.38)
Lactate (mmol/L) 4.7 (2.9-10.5)
Lactate prior to first TPE for each patient 6.3 (4.0-11.7)
Bilirubin (µmol/L)** 80 (54–128)
INR* 2.6 (2.0-4.7)
INR prior to first TPE for each patient* 4.0 (2.2-5.6)
APTT (s)* 50.5 (45.2-58.5)
*One data value missing.
**Six data values missing.
Figure 2 Box plots for temporal trends in (a) MAP, (b) vasopressor
score and (c) VDI for every TPE treatment. The time points extend
from less than 1 hour before TPE (pre treatment), through every hour
of TPE (treatment 1 hr, 2 hr etc.) to 12 hours after TPE (post treatment
1 hr, 2 hr etc.). Note that only a few TPE were as long as 4 or 5 hours
so the data values for treatment 4 hr and 5 hr are calculated from only
a few TPE treatments.zero for these data points. Physiological variables pre-
treatment and 1 hour post-treatment are shown in
Table 3. The effect size of TPE on MAP, vasopressor
score and VDI, comparing 1 hour post-treatment and
12 hours post-treatment with pre-treatment values and
12 hours post-treatment with 1 hour post-treatment
Figure 3 Box plot for temporal trend in VDI for the first TPE
treatment of every patient. The time points extend from less than
1 hour before TPE (pre treatment), through every hour of TPE
(treatment 1 hr, 2 hr etc.) to 12 hours after TPE (post treatment 1 hr,
2 hr etc.). N.B. only a few TPE were as long as 4 or 5 hours so the
data values for treatment 4 hr and 5 hr are calculated from only a
few TPE treatments.
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nificant increase in MAP with treatment (P1 – Pre)
(p = 0.038), but when corrected for vasopressor dose
there was no significant treatment effect on VDI (P1 – Pre)
(p = 0.953). Twelve hours after TPE the VDI was not sig-
nificantly different from baseline (p = 0.214). No asso-
ciation was found between haemodynamic response and
repetition of treatment for the same individual. Analysis of
data including only the 13 patients with paracetamol
toxicity produced results very similar to analysis of all 17
patients (VDI (P1 – Pre) p = 0.865).Table 3 Physiological values pre-TPE (baseline) and
post-TPE (within first hour after treatment)





All TPE 82 (72–92.5) 82 (73.5-96.5)
First TPE for each patient 82 (72–88) 80 (72–92)
Vasopressor score
All TPE 8.35 (3.62-24.6) 10.1 (4.30-25.6)
First TPE for each patient 8.58 (3.34-28.4) 10.0 (4.96-34.3)
VDI
All TPE 0.10 (0.05-0.31) 0.12 (0.05-0.33)
First TPE for each patient 0.13 (0.04-0.34) 0.12 (0.05-0.38)
Heart rate 105 (92.5-111) 112 (92.5-118.5)
Pulse pressure (mmHg) 57 (46.5-69.5) 55 (48.5-71.5)
Central venous pressure (mmHg) 12 (9–16) 11 (9–14)
Patient temperature (Celsius) 36.4 (35.5-37.0) 36.7 (36.1-37.3)
FiO2 0.40 (0.35-0.65) 0.45 (0.325-0.55)Secondary outcomes
The effect of TPE on heart rate, pulse pressure, central
venous pressure, patient temperature, PaO2/FiO2, pH,
lactate, INR and bilirubin are shown in Table 5. Al-
though heart rate, patient temperature, bilirubin and
INR changed significantly with TPE, none of them
remained significantly different from baseline 12 hours
later. The temporal trends in heart rate, pulse pressure,
central venous pressure, patient temperature and cumu-
lative fluid balance from 1 hour before TPE to 12 hours
after TPE are shown in Additional files 1 and 2. There




The principal finding of this study is that in a cohort of
severely ill patients with ALF, TPE did not significantly
affect the amount of vasopressor support required. Al-
though MAP was higher immediately after TPE, the
amount of vasopressor support was also higher, with the
net result that the ratio of the two (VDI) was unaffected.
The same pattern was seen when only the first TPE
treatment for each patient was analysed (see Figure 3).
Secondary findings of this study were a sustained reduc-
tion in INR, a transient reduction in bilirubin, but no
significant change in pH, lactate or oxygenation with
TPE.
Comparison with previous studies
ALF is characterised by a hyperdynamic circulation, with
low systemic vascular resistance, high cardiac index and
low mean arterial pressure [2,3]. In a prospective study
of patients with ALF, Larsen and colleagues found a sig-
nificant increase in MAP, decrease in cardiac index and
decrease in systemic vascular resistance during high-
volume plasmapheresis (TPE) [10,11]. There are several
reasons why our results differed from these findings.
Firstly, paracetamol toxicity was the aetiology of ALF in
13 out of 17 patients in our study compared to 5 out of
16 in the Larsen study. Secondly all of our study patients
received N-acetylcysteine compared to only 10 out of 16
patients in the Larsen study. In a sub-analysis of their
study Larsen and colleagues found no difference in base-
line haemodynamic variables or haemodynamic response
to TPE between patients who received N-acetylcysteine
therapy and those that did not. However, N-acetylcysteine
has been reported to increase mean arterial pressure and
cardiac output in patients with ALF [14]. TPE may have
increased N-acetylcysteine clearance reducing these
haemodynamic effects whilst the patients were receiving
TPE. Thirdly, it is likely that our study population had
more severe vasoplegia than those in Larsen’s study, where
only a minority of patients received vasoactive therapy in
Table 4 Treatment effects on MAP, vasopressor score and VDI relative to baseline valueǂ
VDI Vasopressor score MAP
Effect size (SE) P-value Effect size (SE) P-value Effect size (SE) P-value
Treatment effect (Pre v P1 v P12)† 0.384 0.557 0.025
P1-Pre 0 (0.04) 0.953 0.32 (2.64) 0.904 3.82 (1.85) 0.039
P12- Pre 0.05 (0.04) 0.214 2.77 (2.77) 0.317 −1.12 (1.94) 0.563
P12-P1 0.05 (0.04) 0.235 2.46 (2.77) 0.375 −4.94 (1.94) 0.011
SE: Standard error.
ǂAdjusted for repeated treatments.
†P1-P12: number of hours post treatment.
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Dobutamine (4–14 μg/kg/min) [10,11]. However patients
in our study had a higher baseline MAP (82 ± 72–
92.5 mmHg) than those in Larsen’s study (74 ± 61–
110 mmHg) [10], thus if the vasopressor therapy had been
targeted to a lower MAP in our patients less vasopressor
would have been required. With the small number of
patients studied we were unable to identify a link between
vasopressor requirement at baseline (as a measure of
vasoplegia) and circulatory response to TPE. Fourthly,
Larsen and colleagues used the filtration method of TPE
with a 0.65 μm pore size filter [10,11], whereas at our in-
stitution all TPE was performed using the centrifugal
method. Larsen and colleagues postulated that the hyper-
dynamic circulation in ALF is attributable to a circulating
vasodilating substance or “humoral factor”, perhaps endo-
toxin, with a high molecular weight, or high degree of pro-
tein binding, that could be cleared using the filter used for
TPE [10,11]. Such a substance (or substances) should also
be cleared with centrifugal TPE, however, if the mechan-
ism for vasodilating substance clearance is adsorption ra-
ther than filtration [15], haemodynamic changes may
occur with filter based TPE, that do not occur with centri-
fugal TPE despite the high molecular size clearance. Fur-
thermore, the majority of our patients were also treated
with renal replacement therapy (continuous veno-venous
haemofiltration) before and after TPE, which may have
significantly blunted the potential haemodynamic effect of
TPE [16,17]. Indeed high volume haemodiafiltration is as-
sociated with a rise in blood pressure independent of
acid–base state [18]. Interestingly, in ALF, a single session
of therapy with the molecular adsorbent recirculating
system increases systemic vascular resistance [19,20];
although this effect was not sustained through a second
session [20]. Fifthly, the dose of TPE (volume of plasma
removed) was less than half that used by Larsen and col-
leagues [10,11]. It may be that significant circulatory benefit
is only achieved with “high-volume” plasma exchange [9].
Citrate anticoagulation is routinely used with TPE.
However, citrate accumulation from inadequate hepatic
metabolism can lead to low serum ionized calcium and
hypotension. Severe hypocalcaemia was prevented dur-
ing TPE in our patients by administration of intravenouscalcium as required. The precise haemodynamic effects
of citrate in ALF have not been clearly established [21],
although it appeared to be safe in one study of patients
with liver failure (mostly ALF) supported by a molecular
adsorbent recirculating system [22]. The infusion rate of
citrate in that study was approximately a quarter of the
infusion rate in our study, although the duration of in-
fusion was much longer (median 20 hours). It is possible
that the mild hypocalcaemia observed during TPE in our
study offset possible changes in vasopressor support
levels.
Limitations
The principal weakness was the retrospective nature of
this study. Thus management was unblinded, laboratory
collection times were not standardised and often incom-
plete, TPE was variable in timing, dose, repetition fre-
quency and fluid balance, and vasoactive therapy and
correction of hypocalcaemia were not standardised. The
number of patients and total number of TPE performed
were small. The study population was relatively non-
heterogenous with the majority having paracetamol poi-
soning and all receiving N-acetylcysteine therapy. Renal
replacement therapy was not standardised in timing,
dose or frequency. However, the data were collected
from a cohort of severely ill patients with multiple organ
failure and high risk of death. Furthermore data was col-
lected for up to 12 hours after TPE and for multiple
TPE in the same individual.
A mixed effect model was used to explore the asso-
ciation of baseline pH, lactate and prior renal replace-
ment therapy with haemodynamic response to TPE.
These were considered the baseline variables most likely
to be associated with haemodynamic response to TPE,
either through an association between severity of illness
and response to TPE (pH and lactate), or blunting the
effect of TPE on haemodynamics (renal replacement
therapy). Many other physiological and treatment fac-
tors may also have influenced the response to TPE. In
this retrospective study these factors could not be con-
trolled for.
Power analysis reveals that the study was underpo-
wered to detect significant changes in the primary
Table 5 Baseline measurements and treatment effects
on heart rate, pulse pressure, central venous pressure,
patient temperature, net fluid balance, pH, PaO2/FiO2
ratio, lactate, bilirubin, INR and APTT
Effect size (SE) P-value
Heart rate
Treatment effect (Pre v P1 v P12)† 0.002
P1-Pre 5.15 (1.88) 0.006
P12-Pre −1.12 (1.97) 0.568
P12-P1 −6.28 (1.97) 0.001
Baseline lactate 1.4 (0.39) <0.001
Pulse pressure (mmHg)
Treatment effect (Pre v P1 v P12) 0.456
P1-Pre 0.55 (1.88) 0.772
P12-Pre 2.40 (1.98) 0.226
P12-P1 1.85 (1.98) 0.350
Baseline bilirubin 0.05 (0.01) <0.001
Central venous pressure (mmHg)
Treatment effect (Pre v P1 v P12) <0.001
P1-Pre −1.00 (0.69) 0.146
P12-Pre −2.96 (0.73) <0.001
P12-P1 −1.96 (0.73) 0.007
Baseline bilirubin 0.01 (0.004) 0.007
Temperature (Celsius)
Treatment effect (Pre v P1 v P12) 0.011
P1-Pre 0.41 (0.16) 0.013
P12-Pre −0.04 (0.17) 0.792
P12-P1 −0.45 (0.17) 0.008
Fluid balance (ml)
Treatment effect (Pre v P1 v P12) 0.021
P1-Pre 34.1 (254.1) 0.893
P12-Pre −627.5 (264.9) 0.018
P12-P1 −661.6 (564.9) 0.013
pH
Treatment effect (Pre v P1 v P12) 0.053
P1-Pre 0.03 (0.02) 0.122
P12-Pre 0.04 (0.02) 0.025
P12-P1 0.01 (0.02) 0.798
PaO2/FiO2
Treatment effect (Pre v P1 v P12) 0.073
P1-Pre −0.05 (0.21) 0.801
P12-Pre −0.39 (0.18) 0.029
P12-P1 −0.34 (0.22) 0.118
RRT at baseline −1.40 (0.49) 0.005
Table 5 Baseline measurements and treatment effects
on heart rate, pulse pressure, central venous pressure,
patient temperature, net fluid balance, pH, PaO2/FiO2
ratio, lactate, bilirubin, INR and APTT (Continued)
Lactate (mmol/L)
Treatment effect (Pre v P1 v P12) 0.588
P1-Pre 0.25 (0.57) 0.664
P12-Pre −0.35 (0.46) 0.449
P12-P1 −0.60 (0.62) 0.331
Bilirubin (µmol/L)
Treatment effect (Pre v P1 v P12) 0.026
P1-Pre −44.4 (17.3) 0.010
P12-Pre 5.33 (11.7) 0.649
P12-P1 49.7 (19.3) 0.010
INR
Treatment effect (Pre v P1 v P12) 0.025
P1-Pre −1.55 (0.63) 0.014
P12-Pre −0.90 (0.55) 0.103
P12-P1 0.65 (0.75) 0.383
APTT (s)
Treatment effect (Pre v P1 v P12) 0.421
P1-Pre −1.57 (4.12) 0.703
P12-Pre −4.53 (3.45) 0.189
P12-P1 −2.97 (4.41) 0.501
SE: Standard error.
† P1-P12: number of hours post treatment.
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effects model with effect size and variance of random
effects and residuals estimated from the model, at 5%
significance level with 80% power, 180 TPE treatment
cases would be needed to detect 0.05 unit change in
VDI (i.e. 0.27 to 0.32, 18.5% increase in VDI) in 12 hours
post treatment from the baseline and at least 300 cases
to detect a 3 unit change in vasopressor score in 12
hours post treatment from the baseline. Despite these
calculations a significant effect of TPE on MAP was de-
tected, although, when corrected for vasopressor score
there was no significant difference in VDI.
Implications of study findings
The results of this study question the view that TPE im-
proves systemic haemodynamics in patients with ALF.
However, the single centre, retrospective nature of this
study and small number of patients analysed means that
our findings need to be confirmed in future studies. It is
unclear whether the differences in our results compared
to previous studies are due to differences in patient cha-
racteristics (cause of ALF), other aspects of management
(N-acetylcysteine therapy, renal replacement therapy), se-
verity of illness (vasopressor requirements) or differences
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sus filtration) or method of anticoagulation. Each of these
issues warrant further investigation.
Conclusion
In a single centre series of severely ill patients with ALF,
mostly due to paracetamol poisoning and receiving renal
replacement therapy, TPE did not provide a reduction in
vasopressor requirement. The results of this study ques-
tion the use of TPE to improve systemic haemodynamics
in patients with ALF.
Key messages
 In this small retrospective series of patients with
acute liver failure, therapeutic plasma exchange did
not result in a reduction in vasopressor requirement.
 The findings of this study challenge the view
that therapeutic plasma exchange provides
haemodynamic benefit in patients with acute liver
failure.
 Differences in patient characteristics, or dose and
method of plasma exchange (centrifugal versus
filtration), may explain the difference in findings
between the present study and previous studies.
Additional files
Additional file 1: Figure S1. Box plots for temporal trends in (a) MAP
and (b) vasopressor score for the first TPE treatment for every patient.
Time points extend from less than 1 hour before TPE (pre treatment),
through every hour of TPE (treatment 1 hr, 2 hr etc) to 12 hours after TPE
(post treatment 1 hr, 2hr etc). Note that only a few TPE were as long as 4
or 5 hours so the data values for treatment 4 hr and 5 hr are calculated
from only a few TPE treatments.
Additional file 2: Figure S2. Box plots for temporal trends in (a) heart
rate, (b) pulse pressure, (c) central venous pressure, (d) temperature,
(e) FiO2 and (f) fluid balance. Time points extend from less than 1 hour
before TPE (pre treatment), through every hour of TPE (treatment 1 hr,
2 hr etc) to 12 hours after TPE (post treatment 1 hr, 2hr etc). Note that
only a few TPE were as long as 4 or 5 hours so the data values for
treatment 4 hr and 5 hr are calculated from only a few TPE treatments.
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